MARKET

CYAD

CYAD

Celyad Oncology
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.27
+0.37
+3.74%
Opening 11:29 08/11 EDT
OPEN
10.27
PREV CLOSE
9.90
HIGH
10.31
LOW
10.27
VOLUME
1.20K
TURNOVER
--
52 WEEK HIGH
14.98
52 WEEK LOW
4.100
MARKET CAP
143.19M
P/E (TTM)
-4.2660
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CYAD stock price target is 22.24 with a high estimate of 24.90 and a low estimate of 19.92.

EPS

CYAD News

More
Celyad Oncology reports 1H results
Celyad Oncology (NASDAQ:CYAD): 1H Net loss of €16.6M. Treasury position of €26.7M (-20.8% Y/Y) Press Release
seekingalpha · 4d ago
Celyad Oncology Reports Half Year 2020 Financial Results and Second Quarter Business Highlights
* Interim analysis from alloSHRINK Phase 1 trial demonstrated mPFS of 3.9 months for mCRC patients with MSS disease treated with CYAD-101 following FOLFOX preconditioning; expansion cohort of alloSHRINK trial on-track to begin by fourth quarter 2020 * Phase 1
GlobeNewswire · 4d ago
Celyad Oncology to Announce First Half 2020 Financial Results and Host Conference Call
MONT-SAINT-GUIBERT, Belgium, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today
GlobeNewswire · 08/03 05:00
Ceylad Gets FDA Nod to Begin Phase I Study on CAR T Candidate
Celyad (CYAD) gets the FDA's permission to begin a phase I study on its lead CAR T candidate, CYAD-211, for the treatment of relapsed/refractory multiple myeloma.
Zacks · 07/15 14:34
55 Biggest Movers From Yesterday
Gainers Perceptron, Inc. (NASDAQ: PRCP) shares jumped 107% to close at $6.50 on Tuesday after the company received an order from an automotive supplier for its in-line measurement technology.
Benzinga · 07/15 08:49
Celyad up on advancement of CAR-T candidate CYAD-211
The FDA has signed off on Celyad Oncology SA's (NASDAQ:CYAD) IND for a Phase 1 clinical trial evaluating lead off-the-shelf short hairpin RNA-based allogen
seekingalpha · 07/14 16:41
Celyad Oncology Announces FDA Clearance of IND Application for CYAD-211, First shRNA-based, Non-Gene Edited Allogeneic CAR T Therapy
Celyad Oncology SA (NASDAQ: CYAD) today announced that the company's Investigational New Drug (IND) application for CYAD-211, the company's first-in-class short hairpin RNA (shRNA)-based allogeneic CAR T candidate and second non-gene edited off-the-she
Benzinga · 07/14 09:25
Celyad Oncology Announces FDA Clearance of IND Application for CYAD-211, First shRNA-based, Non-Gene Edited Allogeneic CAR T Therapy
* Phase 1 clinical trial evaluating the off-the-shelf anti-BCMA CAR T candidate CYAD-211 for the treatment of relapsed/refractory multiple myeloma (r/r MM) expected to begin by year-end 2020 * CYAD-211 represents the company’s first allogeneic CAR T clinica
GlobeNewswire · 07/14 05:00

Industry

Biotechnology & Medical Research
-0.71%
Pharmaceuticals & Medical Research
+0.01%

Hot Stocks

Symbol
Price
%Change

About CYAD

Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company's product, C-Cure, allows the differentiation of a patient's own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle. C-Cure consists of autologous adult stem cells guided in vitro to the cardiac lineage before implantation in the failing heart. Furthermore, the Company is involved in the field of immuno-oncology, through its subsidiary, OnCyte.
More

Webull offers kinds of Celyad Oncology stock information, including NASDAQ:CYAD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYAD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CYAD stock methods without spending real money on the virtual paper trading platform.